Johnson & Johnson reported Q1 2026 results with earnings declining despite 9.9% worldwide revenue growth. The company also raised its 2026 revenue guidance midpoint, which offsets the weaker earnings print and supports a modestly positive read-through for the stock.
Johnson & Johnson reported Q1 2026 results with earnings declining despite 9.9% worldwide revenue growth. The company also raised its 2026 revenue guidance midpoint, which offsets the weaker earnings print and supports a modestly positive read-through for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
